Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Trial Profile

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Antithymocyte globulin
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Advanced breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 23 Oct 2017 Planned primary completion date changed from 15 Jun 2017 to 15 Jun 2018.
    • 28 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 15 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top